Literature DB >> 23757311

Mechanism-based engineering against anthracycline cardiotoxicity.

Thomas Force, Yibin Wang.   

Abstract

Entities:  

Keywords:  DNA topoisomerases, type II; Editorials; doxorubicine; ligands; neoplasms; neuregulin-beta; stroke

Mesh：

Substances：

Year:  2013        PMID： 23757311      PMCID： PMC3856339          DOI： 10.1161/CIRCULATIONAHA.113.003688

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  18 in total

1.  'DAUNOMYCIN', A NEW ANTIBIOTIC OF THE RHODOMYCIN GROUP.

Authors:  A DIMARCO; M GAETANI; P OREZZI; B M SCARPINATO; R SILVESTRINI; M SOLDATI; T DASDIA; L VALENTINI
Journal:  Nature       Date:  1964-02-15       Impact factor: 49.962

2.  Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.

Authors:  Douglas B Sawyer; Christian Zuppinger; Thomas A Miller; Hans M Eppenberger; Thomas M Suter
Journal:  Circulation       Date:  2002-04-02       Impact factor: 29.690

3.  Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.

Authors:  Yi Lisa Lyu; John E Kerrigan; Chao-Po Lin; Anna M Azarova; Yuan-Chin Tsai; Yi Ban; Leroy F Liu
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

4.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

5.  Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.

Authors:  Christos Christodoulou; Ioannis Kostopoulos; Haralabos P Kalofonos; Evangelos Lianos; Mattheos Bobos; Evangelos Briasoulis; Helen Gogas; Evangelia Razis; Dimosthenis V Skarlos; George Fountzilas
Journal:  Oncology       Date:  2009-03-05       Impact factor: 2.935

6.  Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Authors:  Sandra M Swain; Fredrick S Whaley; Michael S Ewer
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

Review 7.  Antioxidants and cancer therapy: a systematic review.

Authors:  Elena J Ladas; Judith S Jacobson; Deborah D Kennedy; Katherine Teel; Aaron Fleischauer; Kara M Kelly
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

Review 8.  Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

Authors:  Brian B Hasinoff; Eugene H Herman
Journal:  Cardiovasc Toxicol       Date:  2007       Impact factor: 3.231

9.  An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential.

Authors:  Steven M Jay; Ashwin C Murthy; Jessica F Hawkins; Joshua R Wortzel; Matthew L Steinhauser; Luis M Alvarez; Joseph Gannon; Calum A Macrae; Linda G Griffith; Richard T Lee
Journal:  Circulation       Date:  2013-06-11       Impact factor: 29.690

10.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

Authors:  S E Lipshultz; S D Colan; R D Gelber; A R Perez-Atayde; S E Sallan; S P Sanders
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245
View more
  10 in total

Review 1.  Neuregulin as a heart failure therapy and mediator of reverse remodeling.

Authors:  Cristi L Galindo; Sergey Ryzhov; Douglas B Sawyer
Journal:  Curr Heart Fail Rep       Date:  2014-03

2.  Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities.

Authors:  Nonniekaye Shelburne; Bishow Adhikari; Joanna Brell; Myrtle Davis; Patrice Desvigne-Nickens; Andrew Freedman; Lori Minasian; Thomas Force; Scot C Remick
Journal:  J Natl Cancer Inst       Date:  2014-09-10       Impact factor: 13.506

3.  Bone morphogenetic protein 10 alleviates doxorubicin-induced cardiac injury via signal transducer and activator of transcription 3 signaling pathway.

Authors:  Peng An; Di Fan; Zhen Guo; Fang-Yuan Liu; Chen-Fei Li; Dan Yang; Ming-Yu Wang; Zheng Yang; Qi-Zhu Tang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

4.  Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity.

Authors:  Himangshu Sonowal; Pabitra B Pal; Jian-Jun Wen; Sanjay Awasthi; Kota V Ramana; Satish K Srivastava
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

5.  Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.

Authors:  Chhanda Bose; Sanjay Awasthi; Rajendra Sharma; Helen Beneš; Martin Hauer-Jensen; Marjan Boerma; Sharda P Singh
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

6.  Asiatic Acid Protects against Doxorubicin-Induced Cardiotoxicity in Mice.

Authors:  Xiaoping Hu; Baijun Li; Luocheng Li; Bowen Li; Jinlong Luo; Bin Shen
Journal:  Oxid Med Cell Longev       Date:  2020-05-15       Impact factor: 6.543

7.  Cardiotoxicity of anthracycline therapy: current perspectives.

Authors:  Mihaela Valcovici; Florina Andrica; Corina Serban; Simona Dragan
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

Review 8.  A Review on the Effect of Traditional Chinese Medicine Against Anthracycline-Induced Cardiac Toxicity.

Authors:  Xinyu Yang; Nian Liu; Xinye Li; Yihan Yang; Xiaofeng Wang; Linling Li; Le Jiang; Yonghong Gao; Hebin Tang; Yong Tang; Yanwei Xing; Hongcai Shang
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

9.  TLR9 deficiency alleviates doxorubicin-induced cardiotoxicity via the regulation of autophagy.

Authors:  Zhen Guo; Nan Tang; Fang-Yuan Liu; Zheng Yang; Shu-Qing Ma; Peng An; Hai-Ming Wu; Di Fan; Qi-Zhu Tang
Journal:  J Cell Mol Med       Date:  2020-08-09       Impact factor: 5.310

Review 10.  Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury.

Authors:  M J Cross; B R Berridge; P J M Clements; L Cove-Smith; T L Force; P Hoffmann; M Holbrook; A R Lyon; H R Mellor; A A Norris; M Pirmohamed; J D Tugwood; J E Sidaway; B K Park
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.